Tirzepatide
The dual-agonist that is, on almost every measure, outperforming the monotherapy.
Tirzepatide is the first drug to hit both the GLP-1 and GIP receptors, and the head-to-head data has started reshaping prescribing overnight. The desk tracks the trials, the switch decisions, the compounding picture, and the side-effect profile nobody talks about.
This Week's Feature
Hand-picked by the desk.
Tirzepatide vs. Semaglutide: What the Head-to-Head Evidence Says
Two weekly injections dominate the conversation about diabetes and obesity treatment. When they are compared directly, one tends to come out ahead on weight and blood sugar — but the fuller picture is more nuanced.
Read the feature →